Omega has substantial growth opportunities in the areas of Food Sensitivity,25 Nov 2021 09:06
Omega has substantial growth opportunities in the areas of Food Sensitivity, CD4 testing for the management of people living with HIV, and COVID-19 antibody and antigen testing and provides high quality in-vitro diagnostics products for use in hospitals, clinics, laboratories and healthcare practices in over 75 countries.
Financial Highlights:
· Revenue increased by 81% to £5.73m (H1 '20: £3.16m)
§ Health and Nutrition sales up 62% to £4.17m (H1 '20: £2.58m)
§ Global Health revenue up 170% to £1.56m (H1 '20: £0.58m)
· Gross margin decreased to 34.4% (H1 '20: 42.9%) caused by increased direct labour in anticipation of DHSC COVID-19 contract work
· Statutory loss for the period of £2.75m (H1 '20: £0.28m)
· Adjusted EBITDA loss1 of £2.45m (H1 '20: loss of £1.29m)
· Adjusted loss per share1 of 1.3p (H1 '20: 0.1p)
· Cash balance of £4.7m (H1 '20: £7.0m)